-+ 0.00%
-+ 0.00%
-+ 0.00%

Insili Intelligence (03696): Completed the first case of human administration in an AI-driven exploratory trial of ISM9528, a non-opioid pain relief candidate

Zhitongcaijing·11/17/2026 12:17:16
Listen to the news

According to the Zhitong Finance App, Insili Intelligence (03696) announced that just four months after the pre-clinical drug candidate (PCC) nomination, Insilicon Smart has completed the first human administration of ISM9528. It is a non-opioid pain relief candidate discovered in Abu Dhabi with the potential to become the first of its kind.

This exploratory trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral administration of ISM9528 in healthy adult volunteers. As the research progresses, Insili Intelligence may submit additional documents to relevant authorities and expand this exploratory test subject to regulatory approval.

ISM9528 was nominated as a PCC by the Abu Dhabi team of Insili Intelligence in July 2026, becoming the company's 31st PCC since 2021 and the second PCC resulting from its R&D work in the UAE. In preclinical studies, ISM9528, as a potential oral therapy, has shown superior efficacy to standard treatments in proven models of acute postoperative pain and neuropathic pain. Furthermore, comprehensive in vitro and in vivo safety screening in multiple test combinations and animal models showed good safety characteristics, while rapid systemic absorption and excellent blood-brain barrier permeability support good DMPK characteristics.